Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 13/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | VDR | P11473 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GCK | P35557 | 2/20 | 0.42 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 2/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2662374 | 1.00 | KCNH2 (0.47) | KCNH2THRBPPARGVDRMEN1 | |
| SCHEMBL2646967 | 0.87 | KCNH2 (0.52) | KCNH2GCK | |
| SCHEMBL2645924 | 0.85 | KCNH2 (0.41) | KCNH2MEN1LMNAMAPTHTT | |
| SCHEMBL2662613 | 0.85 | KCNH2 (0.41) | KCNH2MEN1LMNAMAPTHTT | |
| SCHEMBL2646205 | 0.85 | KCNH2 (0.45) | KCNH2THRBPPARGVDRMEN1 | |
| SCHEMBL2644835 | 0.84 | KCNH2 (0.64) | KCNH2MEN1LMNAKMT2AGCK | |
| SCHEMBL2645438 | 0.84 | KCNH2 (0.49) | KCNH2GCK | |
| SCHEMBL2662815 | 0.84 | KCNH2 (0.64) | KCNH2GCK | |
| SCHEMBL2645957 | 0.84 | KCNH2 (0.64) | KCNH2GCK | |
| SCHEMBL2645126 | 0.84 | KCNH2 (0.64) | KCNH2MEN1LMNAKMT2AGCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1169312-B1 | GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-10-06 | — | — | EP | claimed |
| US-6528543-B1 | Glucokinase activating for treating type II diabetes; acylurea compound, phenylacetyl-substituted; 1-(2-(3-chloro-phenyl)-3cyclopentyl-propionyl)-3-methyl-urea | HOFFMAN-LA ROCHE INC. | 2003-03-04 | — | — | US | claimed |
| EP-1169312-B1 | GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-10-06 | — | — | EP | disclosed |
| US-6528543-B1 | Glucokinase activating for treating type II diabetes; acylurea compound, phenylacetyl-substituted; 1-(2-(3-chloro-phenyl)-3cyclopentyl-propionyl)-3-methyl-urea | HOFFMAN-LA ROCHE INC. | 2003-03-04 | — | — | US | disclosed |
| EP-1169312-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000058293-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-05 | — | — | WO | disclosed |